Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
High Park Holdings is a wholly-owned subsidiary of Tilray Brands, focused on the production and distribution of adult-use cannabis products in the Canadian market. Headquartered in London, Ontario, the company operates a world-class, GMP-certified facility designed for large-scale cannabis processing, extraction, and packaging. High Park manages a broad portfolio of consumer brands, including Irisa, Grail, Dubon, and The Batch, catering to diverse consumer preferences across various product formats. The company leverages Tilray's pharmaceutical heritage to maintain rigorous quality standards and safety protocols throughout its manufacturing processes. As a key pillar of Tilray's Canadian operations, High Park is instrumental in driving innovation in cannabis delivery systems and product development. Its strategic focus remains on capturing market share in the legal recreational sector while adhering to strict regulatory compliance.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on High Park Holdings.